Tuesday, October 20-Thursday, October 22
World-renowned lung cancer researcher
2026 Award Recipient
![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Latest News
December 3, 2025
Posts
.@immunosarc of @LurieCancer is leading EA7222, a randomized phase 3 trial of doxorubicin alone or in combination with pembrolizumab in patients with advanced DDLPS, UPS, & related poorly differentiated #sarcomas. More here: https://bit.ly/EA7222 cc: @CureSarcoma
The usual treatment for #OlderAdults with early-stage #melanoma includes two surgeries. The EA6244 study asks: could one surgery + close monitoring be just as effective for some people? More info: https://bit.ly/ea6244-study cc: @YanaNajjarMD @JaniceM10
In the #ComboMATCH Study, researchers are testing if genetically-matched drug combinations will be more effective than single drugs for certain patients with #cancer. Learn more: http://bit.ly/ComboMATCH #PrecisionMedicine #ClinicalTrial
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1400 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
32
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, we are a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
